AI is reshaping biomedical research and drug discovery and delivery. But challenges still exist.
Articles on Drug discovery
Displaying 1 - 20 of 43 articles
Five-thousand-year-old microbes reveal nature’s antibiotic arms race, and hold clues to both the threat of drug resistance and the cure.
Scientists test new drugs to fight silent liver damage.
Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and effective drugs.
Since the 1980s very few antibiotics have been approved. One of the reasons is that there is not enough investment in the sector.
Science has a need to verify results, but DeepMind’s protein prediction tool doesn’t work this way.
The AI model can predict structures for a vast array of the proteins used by living organisms.
There are many ways to kill microbes that cause dangerous infections. Combining genetic screening with machine learning can help researchers identify new antimicrobials.
A marine sponge from Mauritius has shown potential as the source of compounds that kill liver cancer cells.
From rat poison to explosives, many of the drugs we use have interesting origin stories.
Three promising new anti-ageing compounds have been found by artificial intelligence models.
Ancient microbes likely produced natural products their descendants today do not. Tapping into this lost chemical diversity could offer a potential source of new drugs.
Bacterial infections are a growing global challenge. This is due to antibiotic-resistant bacteria, and researchers are turning to AI to develop new drugs.
Despite technological advancements, many challenges remain in getting a drug from lab to pharmacy shelf. Reframing what is a “medicine” could expand treatment options for researchers and patients.
With the dual threats of antibiotic resistance and emerging pandemics, finding new drugs becomes even more urgent. A trove of medicines may be lying under our nose.
Many approved drugs work on the body in ways that researchers still aren’t entirely clear about. Seeing this as an opportunity instead of a flaw may lead to better treatments for complex conditions.
Drug discovery research in Africa receives modest but essential international funding through philanthropic foundations and selected pharmaceutical companies.
While technological advancements have quickened the drug discovery process, some chemical compounds remain a common thorn in a researcher’s side.
Regulatory loopholes for research conducted off US soil allow for questionable trials and misleading data to slip under the FDA’s radar.
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
Top contributors
-
Doctoral Student in Biochemistry, University of Washington
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
-
Assistant Professor of Biochemistry and Molecular Genetics, University of Colorado Anschutz
-
Director of Natural Product Discovery Core; Assistant Professor of Medicinal Chemistry, University of Michigan
-
Postdoctoral Researcher in Chemical and Biological Engineering, Colorado State University
-
Principal Scientist at the Institute for Therapeutics Discovery and Development, University of Minnesota
-
Associate Professor, School of Chemistry, University of Sydney
-
Associate professor, University of Sydney
-
Professor, Abell Chair in Synthetic Biology, Colorado State University
-
Teaching Fellow, University of Surrey
-
Science Writer, Queensland Brain Institute, The University of Queensland
-
Research Professor of Medicinal Chemistry and Associate Program Director of the Institute for Therapeutics Discovery and Development, University of Minnesota
-
PhD Student, University of Liverpool
-
Associate Professor in Mechanical Engineering, Texas A&M University
-
PhD candidate, University of Leicester